Oral and depot progestin therapy for endometriosis: towards a personalized medicine

Laura Buggio, Edgardo Somigliana, Giussy Barbàra, Frattaruolo MP, Maria Pina Frattaruolo, Paolo Vercellini
Expert opinion on pharmacotherapy · 2017 · vol. 18(15) , pp. 1569–1581 · doi:10.1080/14656566.2017.1381086 · PMID:28914561 · W2755238760
Review OA: green CC0 ⤵ 39 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This review examines the clinical efficacy, safety, and tolerability of oral and depot progestins for endometriosis treatment, finding them effective for pain control and a safe, cost-effective option.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis is an estrogen-dependent chronic inflammatory disorder that requires a life-long management plan. Long-term adherence to treatment is pivotal to ensure an effective clinical management. In this optic, one of the cornerstone of endometriosis medical treatment is represented by progestins. Areas covered: This narrative review examines the clinical efficacy, safety and tolerability of oral and depot progestins used in the treatment of endometriosis. The material included in the current manuscript was obtained with a MEDLINE search through PubMed from inception until February 2017. Expert opinion: Progestins are effective in controlling pain symptoms in the majority of women with endometriosis, and their effect seems not inferior to that achieved with other compounds used to treat the disease, such as gonadotropin-releasing hormone agonist. Available progestins include a broad range of both oral and depot compounds, and represent, in most cases, an inexpensive treatment option. In addition, progestins do not increase significantly thrombotic risk and could be adopted in those women with metabolic or cardiovascular contraindication to estrogen-progestins. The choice between the different available compounds should be tailored for every woman with preference to the most cost-effective treatment, depending on the most complained symptom and disease location.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Precision Medicine Progestins Administration, Oral Administration, Oral Clinical Trials as Topic Clinical Trials as Topic Delayed-Action Preparations Delayed-Action Preparations Endometriosis Endometriosis Female Female Humans Humans Pain Pain Pain Precision Medicine Precision Medicine

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (100)

Cited by (39)

Source provenance

europepmc
last seen: 2026-10-14T06:08:39.101224+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:20:36.982799+00:00
License: CC0 · commercial use OK